Welcome to GT: The Podcast! In this episode, Chelvin

Welcome to GT: The Podcast! In this episode,

Rachel Chapman recaps her article, “Tube Erosion,” which was written with Matthew Henderson, MD; Dan Arreaza-Kaufman, MD; Jonathan Eisengart, MD; and Mary Qiu, MD, and was featured in the May/June issue of Glaucoma Today. Glaucoma drainage implants can lower IOP and preserve patients’ vision, but the devices carry the risk of tube erosion, a serious complication that requires prompt surgical management. Ms. Chapman reviews the rates of tube erosion, risk factors, strategies for prevention, and techniques for surgical revision.

On this episode of Survey Says, a special edition of GT: The Podcast, I. Paul Singh, MD, is joined by guests Emily Schehlein, MD, and H. George Tanaka, MD, to review a real case from his practice involving a patient with glaucoma with a history of SLT and MIGS. Though the patient’s IOP is at target, she is very unhappy with topical medication. The group discusses the importance of quality of life and weighs possible next steps, including drug delivery, repeat SLT, surgical intervention, or continuing as is. Later, the guests find out what Dr. Singh did, and they compare their opinions with the results of a social media poll of GT’s audience.

Neeru A. Vallabh, MBBS, FRCOphth, PhD, FEBOS-GL, recaps her article, “The Role of Anterior Segment OCT in MIGS,” which was featured in the March/April issue of Glaucoma Today. Dr. Vallabh explores how this mode of advanced imaging can enhance the patient evaluation and surgical results, reviewing its utility for preoperative evaluation and intraoperative adjustments and its ability to provide insights into postoperative outcomes.

I. Paul Singh, MD; Constance Okeke, MD, MSCE; and Zarmeena Vendal, MD, convene to discuss the latest updates on drug delivery and procedural pharmaceuticals in glaucoma treatment—specifically regarding the intracameral bimatoprost implant (Durysta, AbbVie) and iDose TR (travoprost intracameral implant) 75 mcg (Glaukos). They each explain the role of these treatments in their practices and how to identify the noncompliant patients who are the best candidates for this intervention. They also review safety data behind these treatments and share pearls for getting started.

Editorially independent content supported with advertising by Glaukos. 

Andrew Tatham, MD, MBA, FRCOphth, FEBO, CertLRS, recaps his article, “A Cilioscleral Interpositioning Device,” which was featured in the March/April issue of Glaucoma Today and explores a novel class of glaucoma surgery that targets the supraciliary space. The Intercil Uveal Spacer from Ciliatech represents this new class of surgical implants known as cilioscleral interpositioning devices, or CIDs, which enhance uveoscleral outflow to lower IOP.

On this episode of Survey Says, a special edition of GT: The Podcast, I. Paul Singh, MD, is joined by guests Erin Sieck, MD, and Arkadiy Yadgarov, MD, to review a real case from his practice involving a patient with elevated IOP on medication and a family history of glaucoma. The guests share their initial thoughts and concerns about the patient, discuss their treatment goals, and weigh their options for next steps. Later, they compare their opinions with the results of a social media poll of GT’s audience and find out what Dr. Singh did.

In this episode, two Glaucoma Today contributors dive into the topic of career paths in ophthalmology, comparing different options and offering pearls from their own experiences. Zahra Ali, MD, recaps her article, “Career Change: Making the Vision Come to Life,” which chronicles her personal transition from general ophthalmologist to glaucoma specialist. Then, Devang L. Bhoiwala, MD, recaps his article, “Private Practice Versus Academia,” which outlines the pros and cons of these two distinct career paths.

Flora Hui, PhD, and Pete A. Williams, PhD, recap their article, “Metabolic Dysfunction in Glaucoma: From Bench to Bedside (and Back Again),” which was featured in the January/February issue of Glaucoma Today. IOP lowering treatments are a mainstay of glaucoma management, but, while effective treatments exist, they do not target the neurodegenerative components of the disease. This article discusses the role of metabolic dysfunction in glaucoma and reviews nicotinamide treatment for neuroprotection.